Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in several upcoming virtual investor conferences. Key dates include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021. Investors can access audio webcasts and presentations on Mirum’s Investor website. The company is focused on developing innovative treatments for liver diseases, with its lead candidate, maralixibat, in advanced stages for conditions like Alagille syndrome and PFIC.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences:

SVB Leerink 10^th Annual Global Healthcare Conference
Friday, February 26, 2021 at 3:40 p.m. ET

Raymond James Virtual Institutional Investors Conference
Wednesday, March 3, 2021 at 3:00 p.m. ET

H.C. Wainwright Global Life Sciences Conference
The presentation will be available for viewing on Tuesday, March 9, 2021 at 7:00 a.m. ET.

Oppenheimer 31^st Annual Healthcare Conference
Wednesday, March 17, 2021 at 4:30 p.m. ET

The audio webcasts, on-demand presentation, and an archive of all presentations will be available in the Investors & Media section of Mirum’s website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.

Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005299/en/

FAQ

What investor conferences will Mirum Pharmaceuticals participate in February and March 2021?

Mirum Pharmaceuticals will participate in the SVB Leerink Global Healthcare Conference on February 26, Raymond James Conference on March 3, H.C. Wainwright Conference on March 9, and Oppenheimer Conference on March 17, 2021.

Where can I find the webcasts and presentations from Mirum Pharmaceuticals' investor conferences?

Webcasts and presentations from Mirum's investor conferences will be available in the Investors & Media section of their website at ir.mirumpharma.com.

What is Mirum Pharmaceuticals' focus in biopharmaceuticals?

Mirum Pharmaceuticals focuses on developing and commercializing therapies for debilitating liver diseases.

What is the lead product candidate of Mirum Pharmaceuticals?

Mirum's lead product candidate is maralixibat, aimed at treating Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia.

What regulatory submissions has Mirum Pharmaceuticals made for maralixibat?

Mirum has submitted a New Drug Application (NDA) for maralixibat for treating cholestatic pruritus in patients with Alagille syndrome and a marketing authorization application for pediatric PFIC2 in Europe.